Over 90 Companies Contribute to Crohn's Disease Drug Development Pipeline
A new report indicates that over 90 companies are involved in the development of new treatments for Crohn's disease. More than 90 pipeline drugs are under investigation.
An analytical report reveals that more than 90 companies are actively engaged in the research and development of treatments for Crohn's disease. The "Crohn’s Disease Pipeline Insight 2026" report details over 90 pipeline drugs currently in various stages of clinical development.
The report provides comprehensive insights into these drugs, covering their clinical and non-clinical stages. It assesses therapeutic candidates based on product type, development stage, route of administration, and molecule type. The analysis also identifies inactive pipeline products in the field.
Recent developments include Sanofi's initiation of a Phase 3 induction study for duvakitib in late September 2026, evaluating its efficacy and safety. Concurrently, AbbVie launched a Phase 3 study for risankizumab in pediatric patients, and Eli Lilly and Company began a Phase 2 trial for a combination therapy. Merck Sharp & Dohme LLC is also investigating the efficacy and safety of tulisokibart.
Key players identified in the report include Janssen, Pfizer, AstraZeneca, and Roche. Promising treatments in development feature drugs such as etrasimod and filgotinib. Crohn's disease is a chronic inflammatory condition affecting the gastrointestinal tract.